Talk:Adverum Biotechnologies

Latest comment: 3 years ago by Stonkaments in topic Update Request to Adverum Bio

Update Request to Adverum Bio

edit


  • What I think should be changed: Key People in the box on the right:
  • Why it should be changed: It is no longer accurate:
  • References supporting the possible change (format using the "cite" button):

Update names for accuracy and remove names no longer listed on the website: [1] Laurent Fischer, M.D., Chief Executive officer Leone Patterson, President & Chief Financial Officer Peter Soparkar, J.D., Chief Legal Officer Angela Thedinga, MBA, MPH, Chief Technology Officer

SKM.SamBrown (talk) 20:45, 6 April 2021 (UTC) Suzanne MadoreReply

References

Done. Cordless Larry (talk) 07:13, 7 April 2021 (UTC)Reply

Update Request to Adverum Bio

edit
  • What I think should be changed (include citations):

1. The pipeline listed needs to be updated [1] 2. Text in the first paragraph needs to be updated ...is a clinical-stage gene therapy company headquartered in Redwood City, California with a GMP manufacturing facility in Durham, North Carolina [2].  The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD).[3] and diabetic macular edema (DME) [3].

3. Update to last paragraph: ADVM-022 is currently being evaluated in a Phase 2 trial for DME called INFINITY (NCT04418427).[4]

  • Why it should be changed:

1. It has recently been updated [5] 2. Language has been updated for specificity and legal requests. 3. This is a recent update for ADVM-022

SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)Suzanne Madore, Sam Brown Communications, agency of record for Adverum BioReply

SKM.SamBrown (talk) 13:49, 26 April 2021 (UTC)Reply

Edited to include mention of DME. Also edited the information for conciseness and clarity, as some of the details weren't suitable for the lead section. Stonkaments (talk) 19:34, 26 April 2021 (UTC)Reply